UK pharma to receive parallel scientific advice from MHRA and NICE
This article was originally published in Scrip
The UK Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Clinical Excellence, the country's health technology assessment body, will offer parallel scientific advice to pharmaceutical companies under a new pilot programme.
You may also be interested in...
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.